Information  X 
Enter a valid email address

GlaxoSmithKline PLC (GSK)

  Print      Mail a friend       Annual reports

Tuesday 15 January, 2019

GlaxoSmithKline PLC

Director/PDMR Shareholding

RNS Number : 1709N
GlaxoSmithKline PLC
15 January 2019
 

GlaxoSmithKline plc (the 'Company')

Transaction notification

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 19 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

  

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.3600

199

£15.3600

216

£15.3600

758

£15.3600

199

£15.3600

216

 

  

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

1,588

£15.3600

 

   

e)

Date of the transaction

2019-01-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R G Connor

b)

Position/status

President, Global Vaccines

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 19 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.3600

135

£15.3600

113

£15.3600

161

£15.3600

113

   

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

522

£15.3600

 

   

e)

Date of the transaction

2019-01-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr S P Dingemans

b)

Position/status

Chief Financial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 19 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.3600

263

£15.3600

197

£15.3600

537

£15.3600

263

£15.3600

197

   

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

1,457

£15.3600

 

  

e)

Date of the transaction

2019-01-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr N Hirons

b)

Position/status

SVP, Global Ethics & Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 19 pence each ('Ordinary Shares')

ISIN: GB0009252882

   

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.3600

97

£15.3600

71

£15.3600

84

£15.3600

97

£15.3600

71

  

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

420

£15.3600

 

  

e)

Date of the transaction

2019-01-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr B McNamara

b)

Position/status

CEO, GSK Consumer Healthcare

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053 

  

b)

Nature of the transaction

Increase in notional interest in American Depository Shares following the re-investment of dividends paid to shareholders on 10 January 2019 on American Depository Shares held in the Company's Deferred Annual Bonus Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$ 39.3600

82

$ 39.3600

80

  

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

162

$39.3600

  

e)

Date of the transaction

2019-01-11

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr L Miels

b)

Position/status

President, Global Pharmaceuticals

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 19 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.3600

153

  

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

 

 

 

 

e)

Date of the transaction

2019-01-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 19 pence each ('Ordinary Shares')

ISIN: GB0009252882

    

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019 on Ordinary Shares held in the Company's Performance Share Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.3600

124

£15.3600

90

£15.3600

156

£15.3600

124

£15.3600

90

  

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

584

£15.3600

 

 

e)

Date of the transaction

2019-01-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms K Terrell

b)

Position/status

Chief Digital & Technology Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

ISIN: US37733W1053 

  

b)

Nature of the transaction

Increase in notional interest in American Depository Shares following the re-investment of dividends paid to shareholders on 10 January 2019 on American Depository Shares held in the Company's Deferred Annual Bonus Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$ 39.3600

27

  

d)

Aggregated information

 

Aggregated volume Price

n/a (single transaction)

 

 

 

 

 

  

e)

Date of the transaction

2019-01-11

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms C Thomas

b)

Position/status

SVP, Human Resources

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 19 pence each ('Ordinary Shares')

ISIN: GB0009252882

    

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.3600

181

£15.3600

135

£15.3600

170

£15.3600

181

£15.3600

135

   

d)

Aggregated information

 

Aggregated volume
Price

 

 

 

 

 

 

802
£15.3600

 

 

e)

Date of the

transaction

2019-01-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P C Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 19 pence each ('Ordinary Shares')

ISIN: GB0009252882

   

b)

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 10 January 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£15.3600

111

£15.3600

85

£15.3600

106

  

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

302

£15.3600

 

 

e)

Date of the transaction

2019-01-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHZELFFKFFEBBX

a d v e r t i s e m e n t